USRM (US Stem Cell) EBIT per Share: $-0.01 (TTM As of Dec. 2022)


USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell EBIT per Share?

US Stem Cell USRM -99.00% 12 EBIT per Share is $-0.01 as of Dec. 2022. GuruFocus rates USRM with a GF Score™ of 12/100.

US Stem Cell's EBIT per Share for the three months ended in Dec. 2022 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for US Stem Cell's EBIT per Share or its related term are showing as below:

USRM's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

US Stem Cell's EBIT for the three months ended in Dec. 2022 was $-0.38 Mil.

US Stem Cell  (OTCPK:USRM) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

US Stem Cell EBIT per Share Related Terms

US Stem Cell EBIT per Share Historical Data

* Premium members only.

The historical data trend for US Stem Cell's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Stem Cell EBIT per Share Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.01 -0.01 -0.01 -0.00

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 -0.00 -0.00
USRM
12GF Score
US Stem Cell Inc USRM
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Stem Cell EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

US Stem Cell's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

EBIT per Share(A: Dec. 2022 )
=EBIT/Shares Outstanding (Diluted Average)
=-2.168/591.558
=-0.00

US Stem Cell's EBIT per Share for the quarter that ended in Dec. 2022 is calculated as

EBIT per Share(Q: Dec. 2022 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.375/634.850
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.01 mean?
US Stem Cell (USRM) has a EBIT per Share of $-0.01 as of Dec. 2022. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on US Stem Cell and its competitors.
Is US Stem Cell's EBIT per Share too high?
US Stem Cell's current EBIT per Share is $-0.01. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's EBIT per Share compare to NOVNQ and RGRX?
US Stem Cell's EBIT per Share of $-0.01 can be compared against companies in the Biotechnology industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on US Stem Cell and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. US Stem Cell's current EBIT per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current EBIT per Share of $-0.01. The current EBIT per Share is $-0.01. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For US Stem Cell (USRM), the current EBIT per Share is $-0.01 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price